Annual CFI
$18.00 M
+$21.32 M+641.37%
31 December 2023
Summary:
Heron Therapeutics annual cash flow from investing activities is currently $18.00 million, with the most recent change of +$21.32 million (+641.37%) on 31 December 2023. During the last 3 years, it has fallen by -$190.96 million (-91.39%). HRTX annual CFI is now -91.39% below its all-time high of $208.96 million, reached on 31 December 2020.HRTX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$3.97 M
+$1.92 M+93.85%
30 September 2024
Summary:
Heron Therapeutics quarterly cash flow from investing activities is currently $3.97 million, with the most recent change of +$1.92 million (+93.85%) on 30 September 2024. Over the past year, it has increased by +$27.19 million (+117.10%). HRTX quarterly CFI is now -94.38% below its all-time high of $70.61 million, reached on 30 September 2017.HRTX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$1.54 M
+$27.19 M+94.64%
30 September 2024
Summary:
Heron Therapeutics TTM cash flow from investing activities is currently -$1.54 million, with the most recent change of +$27.19 million (+94.64%) on 30 September 2024. Over the past year, it has dropped by -$30.39 million (-105.34%). HRTX TTM CFI is now -100.74% below its all-time high of $208.96 million, reached on 31 December 2020.HRTX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HRTX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +641.4% | +117.1% | -105.3% |
| 3 y3 years | -91.4% | -81.7% | -101.3% |
| 5 y5 years | +106.5% | -86.1% | -101.4% |
HRTX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -91.4% | +641.4% | -89.2% | +111.0% | -101.3% | +94.8% |
| 5 y | 5 years | -91.4% | +106.5% | -93.8% | +103.1% | -100.7% | +94.8% |
| alltime | all time | -91.4% | +106.5% | -94.4% | +102.7% | -100.7% | +99.5% |
Heron Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.97 M(+93.8%) | -$1.54 M(-94.6%) |
| June 2024 | - | $2.05 M(+60.3%) | -$28.73 M(+63.6%) |
| Mar 2024 | - | $1.28 M(-114.5%) | -$17.56 M(-197.6%) |
| Dec 2023 | $18.00 M(-641.4%) | -$8.84 M(-61.9%) | $18.00 M(-37.6%) |
| Sept 2023 | - | -$23.22 M(-275.7%) | $28.85 M(+80.0%) |
| June 2023 | - | $13.22 M(-64.1%) | $16.03 M(-29.0%) |
| Mar 2023 | - | $36.83 M(+1722.6%) | $22.56 M(-778.8%) |
| Dec 2022 | -$3.32 M(-110.2%) | $2.02 M(-105.6%) | -$3.32 M(-88.8%) |
| Sept 2022 | - | -$36.05 M(-282.5%) | -$29.60 M(-205.4%) |
| June 2022 | - | $19.76 M(+80.5%) | $28.08 M(-41.5%) |
| Mar 2022 | - | $10.95 M(-145.1%) | $48.02 M(+46.7%) |
| Dec 2021 | $32.73 M(-84.3%) | -$24.26 M(-212.1%) | $32.73 M(-71.2%) |
| Sept 2021 | - | $21.63 M(-45.5%) | $113.78 M(-23.2%) |
| June 2021 | - | $39.70 M(-1013.8%) | $148.09 M(+5.2%) |
| Mar 2021 | - | -$4.34 M(-107.6%) | $140.80 M(-32.6%) |
| Dec 2020 | $208.96 M(-1059.3%) | $56.79 M(+1.5%) | $208.96 M(+709.7%) |
| Sept 2020 | - | $55.94 M(+72.6%) | $25.81 M(-1810.2%) |
| June 2020 | - | $32.41 M(-49.2%) | -$1.51 M(-119.0%) |
| Mar 2020 | - | $63.81 M(-150.5%) | $7.92 M(-136.4%) |
| Dec 2019 | -$21.78 M(-92.2%) | -$126.36 M(-541.4%) | -$21.78 M(-119.3%) |
| Sept 2019 | - | $28.63 M(-31.6%) | $112.90 M(-273.8%) |
| June 2019 | - | $41.84 M(+22.7%) | -$64.98 M(-68.2%) |
| Mar 2019 | - | $34.11 M(+309.6%) | -$204.15 M(-26.7%) |
| Dec 2018 | -$278.55 M(-3699.8%) | $8.33 M(-105.6%) | -$278.55 M(-9.3%) |
| Sept 2018 | - | -$149.25 M(+53.3%) | -$307.24 M(+251.6%) |
| June 2018 | - | -$97.33 M(+141.6%) | -$87.38 M(-806.8%) |
| Mar 2018 | - | -$40.29 M(+97.9%) | $12.36 M(+59.8%) |
| Dec 2017 | $7.74 M(-48.0%) | -$20.36 M(-128.8%) | $7.74 M(-76.5%) |
| Sept 2017 | - | $70.61 M(+2829.8%) | $32.91 M(-147.8%) |
| June 2017 | - | $2.41 M(-105.4%) | -$68.85 M(+30.6%) |
| Mar 2017 | - | -$44.92 M(-1033.6%) | -$52.70 M(-454.2%) |
| Dec 2016 | $14.88 M(-126.1%) | $4.81 M(-115.4%) | $14.88 M(-132.1%) |
| Sept 2016 | - | -$31.15 M(-267.8%) | -$46.35 M(+200.0%) |
| June 2016 | - | $18.56 M(-18.1%) | -$15.45 M(-54.5%) |
| Mar 2016 | - | $22.66 M(-140.2%) | -$33.98 M(-40.4%) |
| Dec 2015 | -$56.96 M(+3861.1%) | -$56.42 M(>+9900.0%) | -$56.96 M(+3544.3%) |
| Sept 2015 | - | -$252.00 K(-763.2%) | -$1.56 M(+12.2%) |
| June 2015 | - | $38.00 K(-111.6%) | -$1.39 M(-18.5%) |
| Mar 2015 | - | -$328.00 K(-67.9%) | -$1.71 M(+18.8%) |
| Dec 2014 | -$1.44 M(-14.7%) | -$1.02 M(+1145.1%) | -$1.44 M(+146.2%) |
| Sept 2014 | - | -$82.00 K(-70.5%) | -$584.00 K(-60.5%) |
| June 2014 | - | -$278.00 K(+387.7%) | -$1.48 M(+13.2%) |
| Mar 2014 | - | -$57.00 K(-65.9%) | -$1.31 M(-22.4%) |
| Dec 2013 | -$1.69 M(+73.4%) | -$167.00 K(-82.9%) | -$1.69 M(-13.3%) |
| Sept 2013 | - | -$977.00 K(+821.7%) | -$1.94 M(+85.9%) |
| June 2013 | - | -$106.00 K(-75.6%) | -$1.05 M(+6.3%) |
| Mar 2013 | - | -$435.00 K(+2.1%) | -$984.00 K(+1.2%) |
| Dec 2012 | -$972.00 K(+89.5%) | -$426.00 K(+439.2%) | -$972.00 K(+4.2%) |
| Sept 2012 | - | -$79.00 K(+79.5%) | -$933.00 K(-4.8%) |
| June 2012 | - | -$44.00 K(-89.6%) | -$980.00 K(+4.7%) |
| Mar 2012 | - | -$423.00 K(+9.3%) | -$936.00 K(+82.5%) |
| Dec 2011 | -$513.00 K(+557.7%) | -$387.00 K(+207.1%) | -$513.00 K(+297.7%) |
| Sept 2011 | - | -$126.00 K(<-9900.0%) | -$129.00 K(+95.5%) |
| June 2011 | - | $0.00(0.0%) | -$66.00 K(0.0%) |
| Mar 2011 | - | $0.00(-100.0%) | -$66.00 K(-15.4%) |
| Dec 2010 | -$78.00 K(-112.7%) | -$3000.00(-95.2%) | -$78.00 K(+122.9%) |
| Sept 2010 | - | -$63.00 K(<-9900.0%) | -$35.00 K(-118.6%) |
| June 2010 | - | $0.00(-100.0%) | $188.00 K(-50.9%) |
| Mar 2010 | - | -$12.00 K(-130.0%) | $383.00 K(-37.4%) |
| Dec 2009 | $612.00 K(-9.7%) | $40.00 K(-75.0%) | $612.00 K(-29.9%) |
| Sept 2009 | - | $160.00 K(-17.9%) | $873.00 K(-13.2%) |
| June 2009 | - | $195.00 K(-10.1%) | $1.01 M(+9.7%) |
| Mar 2009 | - | $217.00 K(-27.9%) | $917.00 K(+35.3%) |
| Dec 2008 | $678.00 K(-93.9%) | $301.00 K(+2.7%) | $678.00 K(+92.6%) |
| Sept 2008 | - | $293.00 K(+176.4%) | $352.00 K(-87.5%) |
| June 2008 | - | $106.00 K(-581.8%) | $2.81 M(-55.6%) |
| Mar 2008 | - | -$22.00 K(-12.0%) | $6.34 M(-43.4%) |
| Dec 2007 | $11.20 M | -$25.00 K(-100.9%) | $11.20 M(-13.0%) |
| Sept 2007 | - | $2.75 M(-24.1%) | $12.87 M(+11.4%) |
| June 2007 | - | $3.63 M(-25.0%) | $11.55 M(+56.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2007 | - | $4.84 M(+194.4%) | $7.36 M(-195.4%) |
| Dec 2006 | -$7.72 M(-251.7%) | $1.64 M(+14.4%) | -$7.72 M(-11.6%) |
| Sept 2006 | - | $1.44 M(-358.0%) | -$8.73 M(+4.9%) |
| June 2006 | - | -$557.00 K(-94.6%) | -$8.31 M(+99.7%) |
| Mar 2006 | - | -$10.24 M(-1712.8%) | -$4.16 M(-181.8%) |
| Dec 2005 | $5.09 M(-423.7%) | $635.00 K(-65.6%) | $5.09 M(-37.9%) |
| Sept 2005 | - | $1.85 M(-48.6%) | $8.20 M(+216.1%) |
| June 2005 | - | $3.60 M(-463.1%) | $2.59 M(-139.0%) |
| Mar 2005 | - | -$990.00 K(-126.4%) | -$6.64 M(+322.6%) |
| Dec 2004 | -$1.57 M(-151.3%) | $3.74 M(-199.7%) | -$1.57 M(-70.6%) |
| Sept 2004 | - | -$3.76 M(-33.4%) | -$5.34 M(+983.4%) |
| June 2004 | - | -$5.64 M(-238.2%) | -$493.00 K(-109.9%) |
| Mar 2004 | - | $4.08 M(<-9900.0%) | $5.00 M(+63.3%) |
| Dec 2003 | $3.06 M(-35.1%) | -$25.00 K(-102.3%) | $3.06 M(+209.2%) |
| Sept 2003 | - | $1.09 M(-858.3%) | $991.00 K(-83.0%) |
| June 2003 | - | -$144.00 K(-106.7%) | $5.82 M(+33.5%) |
| Mar 2003 | - | $2.14 M(-202.0%) | $4.36 M(-7.7%) |
| Dec 2002 | $4.72 M(+32.9%) | -$2.10 M(-135.5%) | $4.72 M(-57.1%) |
| Sept 2002 | - | $5.92 M(-469.0%) | $11.00 M(+149.1%) |
| June 2002 | - | -$1.60 M(-164.0%) | $4.41 M(-29.9%) |
| Mar 2002 | - | $2.51 M(-40.0%) | $6.30 M(+77.1%) |
| Dec 2001 | $3.55 M(-60.4%) | $4.18 M(-727.7%) | $3.55 M(-84.2%) |
| Sept 2001 | - | -$665.50 K(-340.6%) | $22.46 M(+146.2%) |
| June 2001 | - | $276.60 K(-218.1%) | $9.12 M(+4.2%) |
| Mar 2001 | - | -$234.20 K(-101.0%) | $8.75 M(-2.5%) |
| Dec 2000 | $8.97 M(-4586.0%) | $23.08 M(-264.8%) | $8.97 M(-163.5%) |
| Sept 2000 | - | -$14.00 M(>+9900.0%) | -$14.12 M(>+9900.0%) |
| June 2000 | - | -$94.20 K(+726.3%) | -$105.60 K(-5.2%) |
| Mar 2000 | - | -$11.40 K(-29.6%) | -$111.40 K(-44.3%) |
| Dec 1999 | -$200.00 K(-87.5%) | -$16.20 K(-200.0%) | -$200.00 K(-192.5%) |
| Sept 1999 | - | $16.20 K(-116.2%) | $216.20 K(+8.1%) |
| June 1999 | - | -$100.00 K(0.0%) | $200.00 K(-140.0%) |
| Mar 1999 | - | -$100.00 K(-125.0%) | -$500.00 K(-68.8%) |
| Dec 1998 | -$1.60 M(+60.0%) | $400.00 K(>+9900.0%) | -$1.60 M(-59.0%) |
| Sept 1998 | - | $0.00(-100.0%) | -$3.90 M(-15.2%) |
| June 1998 | - | -$800.00 K(-33.3%) | -$4.60 M(+142.1%) |
| Mar 1998 | - | -$1.20 M(-36.8%) | -$1.90 M(+90.0%) |
| Dec 1997 | -$1.00 M(+42.9%) | -$1.90 M(+171.4%) | -$1.00 M(-225.0%) |
| Sept 1997 | - | -$700.00 K(-136.8%) | $800.00 K(-27.3%) |
| June 1997 | - | $1.90 M(-733.3%) | $1.10 M(-222.2%) |
| Mar 1997 | - | -$300.00 K(+200.0%) | -$900.00 K(+28.6%) |
| Dec 1996 | -$700.00 K(-150.0%) | -$100.00 K(-75.0%) | -$700.00 K(-800.0%) |
| Sept 1996 | - | -$400.00 K(+300.0%) | $100.00 K(-66.7%) |
| June 1996 | - | -$100.00 K(0.0%) | $300.00 K(-70.0%) |
| Mar 1996 | - | -$100.00 K(-114.3%) | $1.00 M(-28.6%) |
| Dec 1995 | $1.40 M(-255.6%) | $700.00 K(-450.0%) | $1.40 M(-450.0%) |
| Sept 1995 | - | -$200.00 K(-133.3%) | -$400.00 K(0.0%) |
| June 1995 | - | $600.00 K(+100.0%) | -$400.00 K(+33.3%) |
| Mar 1995 | - | $300.00 K(-127.3%) | -$300.00 K(-66.7%) |
| Dec 1994 | -$900.00 K(-108.4%) | -$1.10 M(+450.0%) | -$900.00 K(-125.7%) |
| Sept 1994 | - | -$200.00 K(-128.6%) | $3.50 M(-50.0%) |
| June 1994 | - | $700.00 K(-333.3%) | $7.00 M(-19.5%) |
| Mar 1994 | - | -$300.00 K(-109.1%) | $8.70 M(-18.7%) |
| Dec 1993 | $10.70 M(-174.3%) | $3.30 M(0.0%) | $10.70 M(+101.9%) |
| Sept 1993 | - | $3.30 M(+37.5%) | $5.30 M(-688.9%) |
| June 1993 | - | $2.40 M(+41.2%) | -$900.00 K(-87.5%) |
| Mar 1993 | - | $1.70 M(-181.0%) | -$7.20 M(-50.0%) |
| Dec 1992 | -$14.40 M(-1000.0%) | -$2.10 M(-27.6%) | -$14.40 M(+19.0%) |
| Sept 1992 | - | -$2.90 M(-25.6%) | -$12.10 M(+31.5%) |
| June 1992 | - | -$3.90 M(-29.1%) | -$9.20 M(+73.6%) |
| Mar 1992 | - | -$5.50 M(-2850.0%) | -$5.30 M(-431.3%) |
| Dec 1991 | $1.60 M(+300.0%) | $200.00 K(>+9900.0%) | $1.60 M(-184.2%) |
| Sept 1991 | - | $0.00(0.0%) | -$1.90 M(+1800.0%) |
| June 1991 | - | $0.00(-100.0%) | -$100.00 K(-112.5%) |
| Mar 1991 | - | $1.40 M(-142.4%) | $800.00 K(+100.0%) |
| Dec 1990 | $400.00 K(-123.5%) | -$3.30 M(-283.3%) | $400.00 K(-89.2%) |
| Sept 1990 | - | $1.80 M(+100.0%) | $3.70 M(+94.7%) |
| June 1990 | - | $900.00 K(-10.0%) | $1.90 M(+90.0%) |
| Mar 1990 | - | $1.00 M | $1.00 M |
| Dec 1989 | -$1.70 M | - | - |
FAQ
- What is Heron Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Heron Therapeutics?
- What is Heron Therapeutics annual CFI year-on-year change?
- What is Heron Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Heron Therapeutics?
- What is Heron Therapeutics quarterly CFI year-on-year change?
- What is Heron Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Heron Therapeutics?
- What is Heron Therapeutics TTM CFI year-on-year change?
What is Heron Therapeutics annual cash flow from investing activities?
The current annual CFI of HRTX is $18.00 M
What is the all time high annual CFI for Heron Therapeutics?
Heron Therapeutics all-time high annual cash flow from investing activities is $208.96 M
What is Heron Therapeutics annual CFI year-on-year change?
Over the past year, HRTX annual cash flow from investing activities has changed by +$21.32 M (+641.37%)
What is Heron Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of HRTX is $3.97 M
What is the all time high quarterly CFI for Heron Therapeutics?
Heron Therapeutics all-time high quarterly cash flow from investing activities is $70.61 M
What is Heron Therapeutics quarterly CFI year-on-year change?
Over the past year, HRTX quarterly cash flow from investing activities has changed by +$27.19 M (+117.10%)
What is Heron Therapeutics TTM cash flow from investing activities?
The current TTM CFI of HRTX is -$1.54 M
What is the all time high TTM CFI for Heron Therapeutics?
Heron Therapeutics all-time high TTM cash flow from investing activities is $208.96 M
What is Heron Therapeutics TTM CFI year-on-year change?
Over the past year, HRTX TTM cash flow from investing activities has changed by -$30.39 M (-105.34%)